Table 1.
Characteristics of the included randomized clinical trials.
| Author (year) | Location | No. of eyes (Bev/Con) | Administration route of bevacizumab | Mean age (Bev/Con, y) | Type of pterygium | Follow-up (m) | Treatment method |
|---|---|---|---|---|---|---|---|
| Fallah (2010) | Iran | 26/28 | Topical | 49.96/51.61 | Impending recurrent | 3～6 | Nonsurgery |
| Razeghinejad (2010) | Iran | 15/15 | Subconjunctival | 45.8/41.6 | Primary | 8 vs 7.4 | Conjunctival autograft |
| Banifatemi (2011) | Iran | 22/22 | Subconjunctival | 41.95/44.13 | Primary | 1 | Conjunctival autograft |
| Enkvetchakul (2011) | Thailand | 34/40 | Subconjunctival | 51.5/49 | Primary | 6 | Nonsurgery |
| Shenasi (2011) | Iran | 33/33 | Subconjunctival | 58.67/55.94 | Primary | 9 | Bare sclera |
| Shahin (2012) | Egypt | 20/21 | Subconjunctival | 58.40/57.58 | Primary | 8 | Conjunctivolimbal autograft |
| Lekhanont (2012) | Thailand | 60/20 | Subconjunctival | 48.98/48.27 | Impending recurrent | 3 | Nonsurgery |
| Ozgurhan (2013) | Turkey | 22/22 | Topical | 48.4/50.5 | Recurrent | 6 | Conjunctival autograft |
| Xu (2013) | China | 40/40 | Subconjunctival | 44/41 | Primary | 12 | Conjunctivolimbal autograft |
| Nava-Castaneda, A (2014) | Mexico | 33/16 | Subconjunctival | 48.75/47.8 | Primary | 12 | Conjunctival autograft |
| Karalezli (2014) | Turkey | 42/46 | Topical | 58.82/53.04 | Primary | 29.3 VS 28.5 | Conjunctival autograft |
| Razeghinejad(2014) | Iran | 20/21 | Subconjunctival | 41.95/44.13 | Primary | 6 | Conjunctival autograft |
| Ozsutcu(2014) | Turkey | 30/30 | Subconjunctival | 43.25/41.68 | Primary | 9 | Conjunctival autograft |
| Kasetsuwan(2015) | Thailand | 12/10 | Topical | 50.7/59.3 | Primary | 3 | Bare sclera |
| Hwang(2015) | Korea | 36/33 | Topical | 71.3/73.4 | Primary | 6 | Bare sclera |
| Singh(2015) | India | 30/30 | Subconjunctival | 37.33 | Primary | 3 | Conjunctival autograft |
| Bekibele(2016) | Nigeria | 26/27 | Subconjunctival | 49.2/52.0 | Primary | 18.35 | Conjunctiva autograft |
| Motarjemizadeh(2016) | Iran | 60/30 | Topical | 39.47/40.97 | Primary | 12 | Bare sclera |
Bev: bevacizumab; Con, control; y, year; m, month.